Soluble guanylate cyclase-α1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia

Circulation

Volumn 116, Issue 8, 2007, Pages 936-943

  Vermeersch, Pieter ^a   Buys, Emmanuel ^b,c   Pokreisz, Peter ^a   Marsboom, Glenn ^a   Ichinose, Fumito ^c   Sips, Patrick ^b   Pellens, Marijke ^a   Gillijns, Hilde ^a   Swinnen, Marc ^a   Graveline, Amanda ^c   Collen, Desire ^a   Dewerchin, Mieke ^a   Brouckaert, Peter ^b   Bloch, Kenneth D ^c   Janssens, Stefan ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Guanylate cyclase; Hypertension, pulmonary; Hypoxia; Nitric oxide; Remodeling

Indexed keywords

CYCLIC GMP; GUANYLATE CYCLASE; GUANYLATE CYCLASE ALPHA1; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PROTEIN SUBUNIT; SPERMINE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHRONIC DISEASE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GENOTYPE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE PRESSURE; HEART VENTRICLE REMODELING; HYPOXIA; LUNG BLOOD VESSEL; LUNG VASCULAR RESISTANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STATISTICAL ANALYSIS; SYSTEMIC CIRCULATION; SYSTOLIC BLOOD PRESSURE; TELEMETRY; WILD TYPE;

ACUTE DISEASE; ANIMALS; ANOXIA; ANTIMETABOLITES; BLOOD PRESSURE; BROMODEOXYURIDINE; CHRONIC DISEASE; CYCLIC GMP; DIMERIZATION; FEMALE; GUANYLATE CYCLASE; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; MICE; MICE, MUTANT STRAINS; NITRIC OXIDE; PULMONARY ARTERY; PULMONARY CIRCULATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; VASODILATION; VENTRICULAR FUNCTION, RIGHT;

EID: 34548119854     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.106.677245     Document Type: Article

References (36)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-1436.
2. Reid LM. The pulmonary circulation: remodeling in growth and disease: the 1978 J. Burns Amberson lecture. Am Rev Respir Dis. 1979;119:531-546.
3. Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation. 2004;109:3106-3111.
4. Hofmann F. The biology of cyclic GMP-dependent protein kinases. J Biol Chem. 2005;280:1-4.
5. Koesling D, Russwurm M, Mergia E, Mullershausen F, Friebe A. Nitric oxide-sensitive guanylyl cyclase: structure and regulation. Neurochem Int. 2004;45:813-819.
6. Russwurm M, Koesling D. Guanylyl cyclase: NO hits its target. Biochem Soc Symp. 2004;51-63.
7. Russwurm M, Wittau N, Koesling D. Guanylyl cyclase/PSD-95 interaction: targeting of the nitric oxide-sensitive alpha2beta1 guanylyl cyclase to synaptic membranes. J Biol Chem. 2001;276:44647-44652.
8. Mergia E, Russwurm M, Zoidl G, Koesling D. Major occurrence of the new alpha2beta1 isoform of NO-sensitive guanylyl cyclase in brain. Cell Signal. 2003;15:189-195.
9. Mergia E, Friebe A, Dangel O, Russwurm M, Koesling D. Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular system. J Clin Invest. 2006;116:1731-1739.
10. Steudel W, Ichinose F, Huang PL, Hurford WE, Jones RC, Bevan JA, Fishman MC, Zapol WM. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res. 1997;81:34-41.
11. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG, McMurtry IF. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol. 2004;287:L656-L664.
12. Fagan JM, Rex SE, Hayes-Licitra SA, Waxman L. L-arginine reduces right heart hypertrophy in hypoxia-induced pulmonary hypertension. Biochem Biophys Res Commun. 1999;254:100-103.
13. Liu R, Evgenov OV, Ichinose F. NOS3 deficiency augments hypoxic pulmonary vasoconstriction and enhances systemic oxygenation during one-lung ventilation in mice. J Appl Physiol. 2005;98:748-752.
14. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, Wilkins MR. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 2001;104:424-428.
15. Steudel W, Scherrer-Crosbie M, Bloch KD, Weimann J, Huang PL, Jones RC, Picard MH, Zapol WM. Sustained pulmonary hypertension and right ventricular hypertrophy after chronic hypoxia in mice with congenital deficiency of nitric oxide synthase 3. J Clin Invest. 1998;101:2468-2477.
16. Quinlan TR, Li D, Laubach VE, Shesely EG, Zhou N, Johns RA. eNOS-deficient mice show reduced pulmonary vascular proliferation and remodeling to chronic hypoxia. Am J Physiol Lung Cell Mol Physiol. 2000;279:L641-L650.
17. Lincoln TM, Dey N, Sellak H. Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J Appl Physiol. 2001;91:1421-1430.
18. Oelze M, Mollnau H, Hoffmann N, Warnholtz A, Bodenschatz M, Smolenski A, Walter U, Skatchkov M, Meinertz T, Munzel T. Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res. 2000;87:999-1005.
19. Schulz E, Tsilimingas N, Rinze R, Reiter B, Wendt M, Oelze M, Woelken-Weckmuller S, Walter U, Reichenspurner H, Meinertz T, Munzel T. Functional and biochemical analysis of endothelial (dys)-function and NO/cGMP signaling in human blood vessels with and without nitroglycerin pretreatment. Circulation. 2002;105:1170-1175.
20. Michelakis ED, McMurtry MS, Sonnenberg B, Archer SL. The NO-K+ channel axis in pulmonary arterial hypertension: activation by experimental oral therapies. Adv Exp Med Biol. 2003;543:293-322.
21. Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, Bloch KD, Zapol WM. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation. 2004;110:2253-2259.
22. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398-2403.
23. Lepore JJ, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM, Bloch KD, Semigran MJ. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol. 2002;90:677-680.
24. Buys E, Sips P, Rogge E, Dewerchin M, Brouckaert P. Gender-specific hypertension in mice deficient in the a1 subunit of soluble guanylate cyclase. Circulation. 2004;110 (suppl III):III-307. Abstract.
25. Pokreisz P, Fleming I, Kiss L, Barbosa-Sicard E, Fisslthaler B, Falck JR, Hammock BD, Kim IH, Szelid Z, Vermeersch P, Gillijns H, Pellens M, Grimminger F, van Zonneveld AJ, Collen D, Busse R, Janssens S. Cytochrome P450 epoxygenase gene function in hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling. Hypertension. 2006;47:762-770.
26. Sinnaeve P, Chiche JD, Nong Z, Varenne O, Van Pelt N, Gillijns H, Collen D, Bloch KD, Janssens S. Soluble guanylate cyclase alpha(1) and beta(1) gene transfer increases NO responsiveness and reduces neointima formation after balloon injury in rats via antiproliferative and antimigratory effects. Circ Res. 2001;88:103-109.
27. Bloch KD, Filippov G, Sanchez LS, Nakane M, de la Monte SM. Pulmonary soluble guanylate cyclase, a nitric oxide receptor, is increased during the perinatal period. Am J Physiol. 1997;272:L400-L406.
28. Filippov G, Bloch DB, Bloch KD. Nitric oxide decreases stability of mRNAs encoding soluble guanylate cyclase subunits in rat pulmonary artery smooth muscle cells. J Clin Invest. 1997;100:942-948.
29. Bamberger AM, Koglin M, Kempfert J, Loning T, Scholz H, Behrends S. Expression and tissue localization of soluble guanylyl cyclase in the human placenta using novel antibodies directed against the alpha(2) subunit. J Clin Endocrinol Metab. 2001;86:909-912.
30. Smolenski A, Bachmann C, Reinhard K, Honig-Liedl P, Jarchau T, Hoschuetzky H, Walter U. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J Biol Chem. 1998;273:20029-20035.
31. Li D, Zhou N, Johns RA. Soluble guanylate cyclase gene expression and localization in rat lung after exposure to hypoxia. Am J Physiol. 1999;277:L841-L847.
32. Scotland RS, Madhani M, Chauhan S, Moncada S, Andresen J, Nilsson H, Hobbs AJ, Ahluwalia A. Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo. Circulation. 2005;111:796-803.
33. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, Schramm M, Schroeder W, Schroder H, Stahl E, Steinke W, Wunder F. NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol. 2002;136:773-783.
34. Voelkel NF, Tuder RM. Hypoxia-induced pulmonary vascular remodeling: a model for what human disease? J Clin Invest. 2000;106:733-738.
35. Li D, Laubach VE, Johns RA. Upregulation of lung soluble guanylate cyclase during chronic hypoxia is prevented by deletion of eNOS. Am J Physiol Lung Cell Mol Physiol. 2001;281:L369-L376.
36. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, Schermuly RT. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation. 2006;113:286-295.